PMC8739956_01
Flowchart of patient enrollment, treatment and outcome. CNS, central nerves system; CR, complete remission; CHOP, cyclophosphamide, epirubicin, vindesine, prednisone; DICE, dexamethasone, ifosfamide, carboplatin and etoposide; DHAP, dexamethasone, cytarabine and cis-platinum; HD, high dose; IVLBCL, intravascular large B cell lymphoma; MTX, methotrexate; nd, newly-diagnosed; R, rituximab; PCNSL, primary central nervous system lymphoma; PVRL, primary vitreoretinal lymphoma; PR, partial remission; PD, progressed disease; w/, with; w/o, without; Zan, zanubrutinib.
fonc-11-760405-g001.jpg
PMC8739956_01_fonc-11-760405-g001.jpg
f1
However, the consistency was acceptable between cycles in the same patient ( Figure 5  and  Table S1 ).
MRI features of a secondary CNSL case during zanubrutinib monotherapy. (A) MRI depicts a homogeneously contrast-enhanced mass in the left cerebellum before zanubrutinib administration. (B, C) 7 and 14 days after zanubrutinib, the mass shrank and disappeared.
fonc-11-760405-g002.jpg
PMC8739956_01_fonc-11-760405-g002.jpg
f2
Zanubrutinib was administered only around the operative period; consequently, the lesion in the cerebellum shrank and disappeared within three weeks ( Figure 2 ).
Dynamic change of CSF IL-10 concentrations during the whole treatment.
fonc-11-760405-g003.jpg
PMC8739956_01_fonc-11-760405-g003.jpg
f3
The CSF IL-10 concentration was dramatically decreased by the zanubrutinib monotherapy, which was related to the control of CNS lymphoma and demonstrates the significant anti-tumor activity of zanubrutinib ( Figure 3 ).
Zanubrutinib concentrations of plasma and CSF.
fonc-11-760405-g004.jpg
PMC8739956_01_fonc-11-760405-g004.jpg
f4
The mean plasma concentration of zanubrutinib was 143190.6 +- 93302.7 pg/ml (range, 9281.0-369380.0 pg/ml) at the peak time point median CSF concentration was 2941.1 +- 2382.01 pg/ml (range, 466-9032.0 pg/ml) ( Figure 4 ).
Corrected CSF/plasma ratios for zanubrutinib. (A) 23 paired samples of Corrected CSF/plasma ratio by protein binding rate. (B) Corrected CSF/plasma ratios for zanubrutinib in different patients.
fonc-11-760405-g005.jpg
PMC8739956_01_fonc-11-760405-g005.jpg
f5
However, the consistency was acceptable between cycles in the same patient ( Figure 5  and  Table S1 ).